Daniel D. Burton - Mar 1, 2022 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Mar 1, 2022
Transactions value $
-$354,328
Form type
4
Date filed
3/3/2022, 06:35 PM
Previous filing
Feb 28, 2022
Next filing
May 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Tax liability -$305K -11.4K -3.16% $26.63 350K Mar 1, 2022 Direct F1, F2
transaction HCAT Common Stock Award $0 +3.54K +1.01% $0.00 354K Mar 1, 2022 Direct F3
transaction HCAT Common Stock Award $0 +8.39K +2.37% $0.00 362K Mar 1, 2022 Direct F4
transaction HCAT Common Stock Tax liability -$49.7K -1.86K -0.51% $26.69 361K Mar 2, 2022 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 Represents the weighted average sale price of the shares sold ranging from $26.23 to $27.44 per share, inclusive.
F3 Represents an award of 3,536 performance-based restricted units ("PRSUs") pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each PRSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan and Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2021, the PRSUs noted above vested on March 1, 2022.
F4 Represents an award of 8,385 PRSUs pursuant to the 2019 Plan. Each PRSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan and Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2021, 25% of the PRSUs noted above vested on March 1, 2022 and, thereafter, the remaining 75% of the PRSUs will vest in 12 equal quarterly installments.
F5 Represents the weighted average sale price of the shares sold ranging from $25.29 to $27.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (5).